Behandlungsqualität des Ovarialkarzinoms in Deutschland: Aktuelle Ergebnisse des Qualitätssicherungsprogramms QS OVAR

Mahner, S; Bois, Andreas du; Pfisterer, Jacobus; Hilpert, Felix; Sehouli, Jalid; Lamparter, C; Kerkmann, Markus; Harter, P.

doi:10.1055/s-0039-1693901

Cited by 2 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, a 10-year follow-up in the ACTION trial demonstrated that significantly more cancer-specific deaths were observed only among patients staged sub-optimally [ 12 ]. Similar observations were reported in a nationwide German registry [ 5 ]. In line with this, we confirmed that a lack of both peritoneal biopsies and/or lymphadenectomy increased the risk of disease recurrence.…”

Section: Discussionsupporting

confidence: 90%

“…Complete surgical staging followed by stage-adapted adjuvant treatment significantly improves patients’ 4-year survival [ 5 ]. Omitting surgical steps is critical for two reasons.…”

Section: Introductionmentioning

confidence: 99%

“…Although the importance of optimal surgical staging seems reasonable and surgical steps are clearly defined by the guideline [ 4 ], a relevant number of early-stage OC patients are not treated in accordance with the official recommendations. This seems to be an international dilemma, as several reports from different countries claim that treatment standards are insufficiently applied in the case of early-stage OC [ 5 , 6 ]. Only recently, a nationwide survey by the QS Ovar revealed that only about 70% of patients diagnosed with early-stage OC were operated on in compliance with the national guideline [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

“…This seems to be an international dilemma, as several reports from different countries claim that treatment standards are insufficiently applied in the case of early-stage OC [ 5 , 6 ]. Only recently, a nationwide survey by the QS Ovar revealed that only about 70% of patients diagnosed with early-stage OC were operated on in compliance with the national guideline [ 4 , 5 ]. Although this rate has improved over the last decade, approximately every third of patients diagnosed with apparent early-stage OC has not been treated according to the established standards [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO

Heublein

Baum

Jaeger

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: Surgery is the backbone of early-stage ovarian cancer (OC) management. However, in practice, there is disagreement about the extent of surgical staging and whether additional adjuvant treatment should be provided. As omitting relevant diagnostic or therapeutic procedures might lead to undertreatment, we aimed to structurally investigate treatment practice in addition to prognostic factors in a multicentre series of patients (pts) diagnosed with early-stage OC. Patients: Within this retrospective, multicentre study, medical records of 379 pts who had undergone surgery for suspected early-stage OC between January 2014 and March 2020 were analysed. Results: Of the 379 patients, 292 had pT stage 1a-2a and had complete data on the extent of surgical staging. At least one surgical step was omitted in 100 pts (34.2%). Complete surgical staging (n = 192; (65.8%)) was more often performed in high-grade serous OC and was independent of the healthcare level of the hospital where the initial diagnosis was made. Missing to take peritoneal biopsies was associated with reduced relapse-free-survival in incompletely staged, pT1 cases (p = 0.03). About every second patient (46.7%) with a final stage lower than FIGO IIB and treated with adjuvant chemotherapy received combination chemotherapy. BRCA1 and BRCA2 testing was only performed in a subset of pts, and mutations were detected in 18% (14/79) and 9% (7/85) pts, respectively. Conclusions: This study helps to increase our understanding of early-stage OC treatment and prognosis. In addition to treating patients in compliance with current guidelines, the need for BRCA testing should also be considered for early-stage OC.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Complete surgical staging followed by stage-adapted adjuvant treatment significantly improves patients’ 4-year survival [ 5 ]. Omitting surgical steps is critical for two reasons.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO

Heublein

Baum

Jaeger

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Arguments in favor of IDS are a lower rate of postoperative complications, a lower surgical complexity with reduced procedure time, a lower blood loss and a shorter hospital stay. The value of neoadjuvant chemotherapy with three cycles of carboplatin and paclitaxel followed by interval debulking surgery has been evaluated in four prospective randomized phase IIItrials, whose validity is questioned because of deficiencies in study design and quality of surgical therapy (15)(16)(17)(18)(19)(20). These deficiencies include: Bias with increased inclusion of patients with a poor prognosis; Significantly lower complete resection rates of only 16-19% compared to >50%; Median duration of the operation is only 120 and 165 minutes, which is significantly lower than the expected operating time for a radical debulking operation.…”

Section: Primary Debulking Surgery and Interval Debulking Surgerymentioning

confidence: 99%

Multimodal Treatment of Primary Advanced Ovarian Cancer

Friedrich

Kraft

et al. 2021

Anticancer Res

View full text Add to dashboard Cite

Epithelial ovarian cancer is the second most common malignancy of the female genital tract, with approximately 7,400 new cases annually in Germany. With 5,500 deaths per year, ovarian cancer is the leading gynecologic cause of death. Epithelial ovarian cancer is characterized by morphologic heterogeneity with 4 molecular biological subtypes (immunoreactive-like, differentiated-like, proliferative-like, mesenchymal-like) with different prognosis. Significantly improved survival is achieved by optimal debulking with no residual disease (R0). Systematic lymphonodectomy of clinical negative lymph nodes has no effect on overall survival in advanced ovarian cancer. Interval debulking in advanced ovarian cancer after three cycles of neoadjuvant chemotherapy with carboplatin/paclitaxel is controversial. Standard chemotherapy for advanced ovarian cancer consists of six cycles of carboplatin AUC5 and paclitaxel 175 mg/m 2 , in a three-week cycle. Intraperitoneal chemotherapy is not a standard therapy. Anti-hormonal therapy with an aromatase inhibitor plays a minor role in therapy of both low grade serous ovarian cancer (LGSOC) and high grade serous ovarian cancer (HGSOC). A major achievement in ovarian cancer therapy has been the results of the SOLO-1 trial, in which olaparib as a first line maintenance monotherapy resulted in an overall 70% lower risk of disease progression in patients with advanced Breast Cancer Gene (BRCA)-mutated ovarian cancer.Epithelial ovarian cancer is the second most common malignant disease of the female genital tract in Germany with approximately 7,400 new cases annually. Thus, one in 75 women will develop ovarian cancer during her lifetime. With 5,500 deaths annually, ovarian cancer is the leading gynecologic cause of death (1).Over the past 15 years, the quality of treatment for ovarian cancer has been continuously improving. Median PFS has increased from 12.7 months in 2004 to 20.7 months in 2016 in FIGO stages III and IV. Treatment at an experienced center and an optimal tumor reduction during primary surgery is not least responsible for this (2). Experience of Treatment CenterTreatment center experience plays a crucial role in ovarian cancer therapy. In 2014 Bristow et al. (6) proved that patients 3253 This article is freely accessible online.

show abstract

Behandlungsqualität des Ovarialkarzinoms in Deutschland: Aktuelle Ergebnisse des Qualitätssicherungsprogramms QS OVAR

Cited by 2 publications

References 0 publications

Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO

Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO

Multimodal Treatment of Primary Advanced Ovarian Cancer

Contact Info

Product

Resources

About